Radically Simplifying Production Of hMSC-EVs With Rapid Clinical Translation & Scale-up Potential

Extracellular Vesicles from MSCs have been shown to deliver therapeutic effects similar to parent hMSCs. Several clinical trials have been started to date using MSC-derived EV materials manufactured under Good Manufacturing Practices. The main challenge that researchers face when investigating EVs is generating sufficient quantities to explore both characterization and functional studies in applied research and product development. This presentation highlights strategies and systems that radically simplify the production of large quantities of EVs, as well as cGMP raw material requirements for rapid clinical translation.